Isamoltane

Isamoltane
Clinical data
Other names	Isamoltan; CGP-361A; CGP361A
Drug class	Beta blocker; Serotonin 5-HT1A receptor antagonist; Serotonin 5-HT1B receptor antagonist
ATC code	None;
Identifiers
	IUPAC name 1-(propan-2-ylamino)-3-(2-pyrrol-1-ylphenoxy)propan-2-ol;
CAS Number	99740-06-4;
PubChem CID	127403;
ChemSpider	113051;
UNII	214SP5P1EX;
CompTox Dashboard (EPA)	DTXSID00912513 ;
Chemical and physical data
Formula	C16H22N2O2
Molar mass	274.364 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES OC(CNC(C)C)COc1ccccc1n2cccc2;

Isamoltane (developmental code name CGP-361A) is a beta blocker (β-adrenergic receptor antagonist) with additional serotonin 5-HT_1A and 5-HT_1B receptor antagonist activity.^[1]^[2] It has about 5-fold higher affinity for the serotonin 5-HT_1B receptor (K_i = 21 nM) over the serotonin 5-HT_1A receptor (K_i = 112 nM).^[3] It has anxiolytic effects in rodents.^[4] The drug was under development by Novartis and AstraZeneca for the treatment of anxiety disorders in the 1990s but was never marketed.^[1]